CKD患者骨折的诊断、治疗与预防:欧洲钙化组织学会与ERA-EDTA综述
该综述由欧洲钙化组织学会与欧洲肾脏协会成员撰写,聚焦慢性肾脏病(CKD)患者骨折的诊断、治疗与预防。文章指出CKD矿物质骨病普遍存在,传统与CKD相关危险因素叠加增加共病和死亡风险,但临床与生化干预目标仍存争议,导致骨脆性管理不足。维生素D补充广泛使用但获益证据有限,新型生物标志物如硬化素和FGF23前景可期但尚未确立。
要点
- CKD患者矿物质骨病普遍,骨折风险与死亡风险增加。
- 维生素D补充广泛使用,但仅少数研究显示减少骨折和死亡。
- 新型骨脆性标志物(硬化素、FGF23)尚需进一步验证。
核心结论
- CKD患者骨脆性管理不足,临床与生化干预目标仍存争议。
- 多学科临床专家合作对成功预防骨折至关重要。
- 需新信息阐明矿物质代谢紊乱对骨强度的影响。
研究设计与样本
- 欧洲钙化组织学会与欧洲肾脏协会成员撰写的文献综述。
主要发现
- 矿物质骨病在CKD患者中普遍存在,导致骨痛和骨折等表现。
- 传统危险因素与CKD相关因素叠加增加共病和死亡风险。
- 维生素D补充广泛使用,但仅少数研究显示减少骨折和死亡。
- 控制甲状旁腺激素可改善骨矿化并降低碱性磷酸酶等生物标志物。
关键数值与推荐
- 推荐CKD患者达到25-羟基维生素D血清水平以降低高甲状旁腺激素水平。
- 高甲状旁腺激素水平与骨骼骨折相关。
- 硬化素和成纤维细胞生长因子23作为骨脆性替代标志物的价值尚未确立。
临床怎么用
- 临床应关注CKD患者骨脆性评估与管理。
- 可监测并纠正25-羟基维生素D水平以控制甲状旁腺激素。
- 控制甲状旁腺激素以改善骨矿化并降低骨转换标志物。
局限性
- 多数临床与生化干预目标仍存争议。
- 维生素D补充减少骨折和死亡的证据仅来自少数研究。
- 新型生物标志物的价值尚未 firmly established。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mineral and bone disease is omnipresent in patients with chronic kidney disease (CKD) and leads to a diverse range of clinical manifestations, including bone pain and fractures. The accumulation of traditional clinical risk factors, in addition to those related to CKD, enhances the risk of comorbidity and mortality. Despite significant advances in understanding bone disease in CKD, most clinical and biochemical targets used in clinical practice remain controversial, resulting in an undermanagement of bone fragility. Vitamin D supplementation is widely used, but only a few studies have shown beneficial effects and a reduced risk of fracture and mortality. The achievement of serum levels of 25-hydroxyvitamin D is recommended for CKD patients to reduce a high parathyroid hormone level, which is associated with skeletal fractures. Optimal control of parathyroid hormone also improves bone mineralization and lowers circulating bone biomarkers such as alkaline phosphatase and cross-linked collagen type I peptide. The potential value of more recent biomarkers such as sclerostin and fibroblast growth factor 23, as surrogates for bone fragility, is an encouraging new direction in clinical research but is far from being firmly established. This article reviews the literature related to the pathophysiological role of various mineral and biochemical factors involved in renal osteodystrophy. To better understand bone fragility in CKD, new information related to the impact of disturbances of mineral metabolism on bone strength is urgently needed. The combined expertise of clinicians from various medical disciplines appears crucial for the most successful prevention of fractures in these patients.
引用
- Pimentel A, Ureña-Torres P, Zillikens MC, et al. Fractures in patients with CKD-diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation. Kidney Int. 2017. PMID: 28964571. doi:10.1016/j.kint.2017.07.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。